Welcome to our dedicated page for Neuraxis SEC filings (Ticker: NRXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeurAxis, Inc. (NRXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. NeurAxis is a medical technology company focused on neuromodulation therapies, including its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology and IB-Stim device for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older.
Through this page, users can review current and historical reports such as Form 8-K filings, which NeurAxis uses to announce material events. Recent 8-Ks describe FDA 510(k) clearance for expanded PENFS indications in patients aged 8 years and older, including adults, and outline the significance of this clearance as the first FDA clearance or approval for a treatment specifically addressing functional dyspepsia in the adult patient population. Other 8-Ks detail capital markets activity, including an At The Market Offering Agreement under a shelf registration statement on Form S-3, preliminary financial estimates, and the termination of a license and collaboration agreement related to the NSS-2 Bridge device.
Investors can also use this filings page to monitor financing structures and equity programs, such as updates to the at-the-market offering capacity and the adoption of the NeurAxis, Inc. 2025 Employee Stock Purchase Plan. These documents explain how the company may issue common stock, the role of its sales agent, applicable commissions, and share limits under employee purchase arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of new 8-Ks, registration statements, and related exhibits. Real-time updates from EDGAR ensure that new NeurAxis filings appear promptly, while structured access to exhibits, legal opinions, and financial disclosures supports deeper analysis of the company’s regulatory, financing, and operational developments.
Neuraxis, Inc. is calling a 2026 annual stockholder meeting on June 10, 2026 to elect six directors and conduct key governance votes. Holders of 11,505,421 shares of Common Stock and 3,796,907 shares of Series B Preferred Stock as of April 14, 2026 may vote, with total voting power of 13,883,480 votes.
The board asks stockholders to ratify Rosenberg Rich Baker Berman, P.A. as auditor, expand the 2022 Omnibus Securities and Incentive Plan from 1,482,152 to 3,400,000 authorized shares and extend its evergreen feature to 2033, approve a 2025 Employee Stock Purchase Plan, and allow potential adjournment to solicit additional proxies.
Neuraxis, Inc. increased the capacity of its existing at-the-market stock offering program. The company may now sell shares of its common stock for an aggregate offering price of up to $11,500,000 through Craig-Hallum Capital Group LLC under a previously effective Form S-3 shelf registration.
The agreement was originally sized at up to $6,270,000. From August 29, 2025 through April 20, 2026, Neuraxis sold 1,125,281 shares of common stock under this arrangement. A new prospectus supplement and a related legal opinion from Lucosky Brookman LLP support the expanded program.
Neuraxis, Inc. released preliminary, unaudited figures for the quarter ended March 31, 2026. The Company expects cash and cash equivalents of about $7.1 million as of that date, providing a snapshot of its available liquidity.
For the same three-month period, Neuraxis anticipates net sales of approximately $1.6 million, up from about $0.9 million a year earlier, showing strong year-over-year revenue growth. On a preliminary basis, it expects gross profit of about $1.4 million and an operating loss of about $1.7 million, indicating the business is still not profitable.
The Company emphasizes these numbers are preliminary and unaudited and may change as the quarter-end close is completed and the independent registered public accounting firm reviews the full financial statements.
Neuraxis, Inc. amends its prospectus supplement to increase its at-the-market offering capacity to up to $11,500,000 of Common Stock to be sold from time to time through Craig-Hallum Capital Group LLC under an existing Sales Agreement.
The supplement states the company sold $5.8 million of securities under the Sales Agreement from August 29, 2025 through April 20, 2026. Preliminary unaudited results show cash and cash equivalents of approximately $7.1 million as of March 31, 2026, net sales of about $1.6 million for the three months ended March 31, 2026 (versus $0.9 million for the comparable prior-year period), preliminary gross profit of $1.4 million, and a preliminary operating loss of $1.7 million for that quarter. The filing discloses a public float of $66,876,930 based on 11,505,421 shares outstanding as of April 20, 2026.
Neuraxis, INC Chief Financial Officer buys company stock in open market trade. On April 1, 2026, CFO Timothy Robert Henrichs purchased 7,593 shares of Neuraxis common stock in an open-market transaction at a price of $1.96 per share. Following this purchase, he directly owns 7,593 shares.
Neuraxis, INC executive Thomas Joeseph Carrico, who serves as CRO, CCO and CPO, bought 667 shares of the company’s common stock in an open-market purchase at $1.96 per share. Following this transaction, he directly holds a total of 331,903 common shares.
Neuraxis, INC Chief Executive Officer Brian Allen Carrico purchased additional company stock in the open market. On April 1, 2026, he bought 8,060 shares of Neuraxis common stock at $1.96 per share.
After this transaction, Carrico directly owns 348,178 shares of Neuraxis common stock, modestly increasing his personal stake in the company.
Neuraxis, Inc. develops drug-free neuromodulation devices for chronic gastrointestinal and pain conditions, focusing initially on pediatric patients with disorders of gut-brain interaction. Its lead product, IB-Stim, is an FDA Class II PENFS device for functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia in patients 8 years and older.
The company has also launched RED (Rectal Expulsion Device) for office-based assessment of pelvic floor dysfunction and rectal hypersensitivity in adults, and has additional PENFS indications in randomized trials, including post-concussion syndrome, cyclic vomiting syndrome, post-operative opioid-sparing pain control and fibromyalgia.
IB-Stim is priced at $1,195 per device, or $4,780 per standard four-device treatment course. Key access milestones include a Category I CPT code 64567 effective January 1, 2026, inclusion of PENFS as the only FDA-cleared treatment in NASPGHAN pediatric functional abdominal pain guidelines, and a Federal Supply Schedule contract for IB-Stim. As of March 12, 2026, Neuraxis had 11,187,639 common shares outstanding, and non-affiliate equity was valued at approximately $20.4 million at its most recent second-quarter end.
Neuraxis, Inc. reported that executive Adrian Miranda, its CMO and SVP of Science & Technology, acquired 47,569 restricted stock units (RSUs) on January 22, 2026. These equity awards were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan.
The RSUs vest in three equal annual installments over a three-year period, aligning Miranda’s compensation with longer-term company performance. After this grant, Miranda directly holds 47,569 derivative securities linked to Neuraxis common stock.